New Books in Neuroscience: Robert-Jan Smits and Rachael Pells, "Plan S for Shock: Science. Shock. Solution. Speed." (Ubiquity Press, 2022)

Listen here to New Books in Neuroscience, a podcast from New Books Network featuring interviews with neuroscientists about their new books. For more information, visit New Books in Neuroscience.

Originally released: June 21, 2022

Plan S: the open access initiative that changed the face of global research.

Robert-Jan Smits and Rachael Pells's book Plan S for Shock: Science. Shock. Solution. Speed. (Ubiquity Press, 2022) tells the story of open access publishing - why it matters now, and for the future. In a world where information has never been so accessible, and answers are available at the touch of a fingertip, we are hungrier for the facts than ever before - something the Covid-19 crisis has brought to light. And yet, paywalls put in place by multi-billion dollar publishing houses are still preventing millions from accessing quality, scientific knowledge - and public trust in science is under threat. On 4 September 2018, a bold new initiative known as 'Plan S' was unveiled, kickstarting a world-wide shift in attitudes towards open access research. For the first time, funding agencies across continents joined forces to impose new rules on the publication of research, with the aim of one day making all research free and available to all. What followed was a debate of global proportions, as stakeholders asked: Who has the right to access publicly-funded research? Will it ever be possible to enforce change on a multi-billion dollar market dominated by five major players? Here, the scheme's founder, Robert-Jan Smits, makes a compelling case for Open Access, and reveals for the first time how he set about turning his controversial plan into reality - as well as some of the challenges faced along the way. In telling his story, Smits argues that the Covid-19 crisis has exposed the traditional academic publishing system as unsustainable.

Host Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland.

We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode’s original release date.